Skip to main content

Table 1 Patient characteristics at the time of primary diagnosis of breast cancer

From: Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer

  Patients (%) LOH (%)§ DTC (%)$
Total 81 27 (33.5) 32 (39.5)
Age 56 years (range 33-81)   24 (41)
Family history    4 (31)
   negative 58 (73) 21 (36) 4 (50)
   positive 13 (17) 5 (39)  
   unknown 8 (10) 1 (13) 28 (37)
Patient subgroup    
   M0 76 (94) 27 (36)  
   M1 5 (6) 0 (0) 4 (80)
Tumor size    
   pT1 33 (41) 14 (42) 11 (33)
   pT2 39 (48) 12 (31) 17 (44)
   pT3-4 9 (11) 1 (11) 4 (44)
Nodal status    
   pN0 49 (62) 19 (39) 21 (43)
   pN1-2 30 (38) 8 (27) 10 (33)
Histology    
   Ductal 60 (75) 23 (38) 20 (33)
   Lobular 10 (12.5) 3 (30) 6 (60)
   Others* 10 (12.5) 1 (10) 6 (60)
Grading    
   I-II 51 (65) 23 (45) 21 (41)
   III 28 (35) 4 (14) 10 (36)
ER status    
   negative 23 (28.5) 6 (26) 9 (39)
   positive 58 (71.5) 21 (36) 23 (40)
PR status    
   negative 29 (36) 8 (28) 8 (28)
   positive 52 (64) 19 (37) 24 (46)
CEA    
   negative 69 (86) 25 (36) 27 (39)
   positive 11 (14) 2 (18) 5 (46)
CA15-3    
   negative 67 (84) 25 (37) 27 (40)
   positive 13 (16) 2 (15) 5 (39)
Therapy    
   BCT 45 (56) 20 (44) 14 (31)
   Ablation 36 (44) 7 (22) 18 (50)
  1. *n = 5 tumors were characterized as mixed ductal/lobular carcinomas of the breast; in five tumors histology was unknown. Among these five tumors were three cases of inflammatory breast cancer and one case of a carcinoma sarcoma of the breast with unknown histological subtype.
  2. §total loss of heterozygosity (LOH) detected at all six markers in blood
  3. $ disseminated tumor cells (DTC) detected in bone marrow
  4. BCT = breast conserving therapy; CEA = carcino embryonal antigen; ER = estrogen receptor; PR = progesterone receptor.